Version 1
: Received: 4 February 2024 / Approved: 5 February 2024 / Online: 5 February 2024 (07:46:53 CET)
How to cite:
Ferrari, I.V. Exploring Natural Compounds for Alzheimer's Disease: Virtual Screening and Docking Study with KIBRA Protein. Preprints2024, 2024020232. https://doi.org/10.20944/preprints202402.0232.v1
Ferrari, I.V. Exploring Natural Compounds for Alzheimer's Disease: Virtual Screening and Docking Study with KIBRA Protein. Preprints 2024, 2024020232. https://doi.org/10.20944/preprints202402.0232.v1
Ferrari, I.V. Exploring Natural Compounds for Alzheimer's Disease: Virtual Screening and Docking Study with KIBRA Protein. Preprints2024, 2024020232. https://doi.org/10.20944/preprints202402.0232.v1
APA Style
Ferrari, I.V. (2024). Exploring Natural Compounds for Alzheimer's Disease: Virtual Screening and Docking Study with KIBRA Protein. Preprints. https://doi.org/10.20944/preprints202402.0232.v1
Chicago/Turabian Style
Ferrari, I.V. 2024 "Exploring Natural Compounds for Alzheimer's Disease: Virtual Screening and Docking Study with KIBRA Protein" Preprints. https://doi.org/10.20944/preprints202402.0232.v1
Abstract
Therapies targeting amyloid, such as monoclonal antibodies like Lecanemab, Aducanumab, and Donanemab, have garnered FDA approval but remain controversial due to limited clinical benefits and significant side effects against Alzheimer. The present theorical work utilized Virtual Screening and Docking techniques to explore potential small natural molecules' interactions with the KIBRA protein, a promising target for drug development. Kibra protein is considered a biomarker for synaptic dysfunction and cognitive decline.Employing Autodock Vina and Pyrx software, on several natural compounds and found Hypericin to exhibit the lowest binding energy of approximately -9 kcal/mol. Previous studies have highlighted Hypericin's strong affinity for Alzheimer's Disease-associated targets like ABAD and BACE1. These findings suggest Hypericin could be as a potential therapeutic agent for Alzheimer's Disease. Further research is warranted to validate its efficacy and safety for clinical use.
Keywords
Hypericin,Autodock Vina,Alzheimer's Disease,KIBRA Protein
Subject
Public Health and Healthcare, Other
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
